How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,484 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. No Additional Benefit of Combining Fractional Carbon Dioxide Laser With Narrow-Band Ultraviolet B Phototherapy for Vitiligo: A Randomized Prospective Study With Half-Body Side Comparison. (PubMed)

No Additional Benefit of Combining Fractional Carbon Dioxide Laser With Narrow-Band Ultraviolet B Phototherapy for Vitiligo: A Randomized Prospective Study With Half-Body Side Comparison. Narrow-band ultraviolet B (nb-UVB) phototherapy constitutes the gold standard treatment for vitiligo. Whether carbon dioxide (CO2) laser might increase the efficacy of nb-UVB is still a topic of debate.To test the hypothesis that the addition of fractional CO2 laser to nb-UVB may enhance (...) repigmentation.Fractional CO2 laser was applied with an interval of 2 weeks for 7 sessions, only to 1 of the 2 symmetrical vitiligo patches located on 2 different half-body sides. Patients received whole-body nb-UVB phototherapy 3 times a week, for at least 4 months. Repigmentation was scored with a quartile grading scale, with the help of a computer program using the photographs taken by the digital dermatoscope.Fifty-one symmetrical vitiligo patches of 30 patients were included. No statistically significant

2019 Dermatologic Surgery

42. Systematic Review of Clinimetric Instruments to determine the severity of Non-segmental Vitiligo. (PubMed)

Systematic Review of Clinimetric Instruments to determine the severity of Non-segmental Vitiligo. This systematic review of measurement instruments for vitiligo outcomes included validation articles published from 2011 to May 2018. According to the PRISMA statement, the search was carried out in EMBASE (via OvidSP); MEDLINE (via OvidSP and PubMed). The COSMIN taxonomy will be used to define the measurement properties. Inclusion criteria were original studies reporting measuring properties (...) . Exclusion criteria were clinical trials using scales whose measurement properties were not assessed, studies of cross-cultural adaptation, scales focused on other aspects of the disease such as quality of life, satisfaction, disease's burden. Fourteen studies were identified, which described 15 instruments to measure vitiligo outcomes. Nine of them, measured properties related to the severity of the disease: Vitiligo extent score (VES), Self-Assessment Vitiligo Extent Score (SA-VES), Self-Assessed

2019 Australasian Journal of Dermatology

43. T-cell responses against 4-tertiarybutylphenol-exposed pigmented cells in a patient with occupational vitiligo. (PubMed)

T-cell responses against 4-tertiarybutylphenol-exposed pigmented cells in a patient with occupational vitiligo. Several case studies on contact/occupational vitiligo after skin contact with 4-tertiairybutylphenol (4-TBP) have been reported. Biochemical and cellular effects of 4-TBP on melanocytes have been shown in vitro, but immunological analyses explaining the immunising ability of 4-TBP leading to wide-spread vitiligo lesions beyond areas of primary contact are still lacking. We report here (...) the presence of a systemic T-cell response to 4-TBP-exposed pigmented cells in a patient with chemically-induced vitiligo. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

44. Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells. (PubMed)

Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells. Vitiligo is an autoimmune disease with varying pathological features. Activation of the CCL20-CCR6 axis plays an important role in chronic inflammatory diseases. However, whether CCL20-CCR6 and Th1/17 cells are indicative of active vitiligo is unclear.To investigate the potential role of CCL20 and the involvement of Th1/17 and Tc1/17 cells in the mechanism in vitiligo.One hundred patients (...) with vitiligo, and 20 healthy controls were included. The serum and blister fluid IL-17, IFN-γ, CCL20, and CXCL10 were studied using enzyme-linked immunosorbent assays. The numbers of Th1/17 cells and Tc1/17 cells in circulation were quantified using flow cytometry. CCR6 mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and the protein level was confirmed by western blotting. CCR6 and CCL20 expression in lesions was analyzed by immunohistochemistry.The

2019 Journal of dermatological science

45. Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in Vitiligo patients; positive association with disease activity. (PubMed)

Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in Vitiligo patients; positive association with disease activity. The contribution of immune checkpoint receptors in the immunopathogenesis of various autoimmune diseases has been addressed in previous reports. To investigate the expression profile of T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) and programmed cell death-1 (PD-1) checkpoint molecules in CD8+ T-cells of Vitiligo patients. The association of Tim-3 (...) and PD-1 expression with disease activity was also explored. The frequency of Tim-3+ /PD-1+ /CD8+ T-cells in 30 Vitiligo patients and 30 sex- and age-matched controls was determined by flow cytometry. CD8+ T cells were then positively isolated by magnetic beads and the mRNA expression of PD-1 and Tim-3 was determined by TaqMan-based Real-Time PCR. To measure the cytokines production, PBMCs were stimulated with PMA/ionomycin and concentrations of IL-4, IFN-γ and TNF-α were measured in culture

2019 Experimental Dermatology

46. Extracellular fraction of adipose tissue as an innovative regenerative approach for vitiligo treatment. (PubMed)

Extracellular fraction of adipose tissue as an innovative regenerative approach for vitiligo treatment. Vitiligo is a common, disfiguring autoimmune disease that negatively affects patients' self-esteem and quality of life. Current treatments are moderately effective in reversing disease and promoting melanocyte regeneration. Thus, therapeutic advanced strategies are emerging from regenerative medicine. It has recently emerged that adipose tissue secretome may be used as a cell-free therapy (...) in skin regeneration since paracrine functions of adipose-derived stem cells (ADSCs) alone are responsible for most of the therapeutic effect of stem cells in several animal disease models. In this study, we tested the effect of adipose tissue extracellular fraction (AT-Ex) isolated from lipoaspirates on dermal and epidermal vitiligo cells in vitro. Using this experimental model, we demonstrated that molecules secreted by adipose tissue ameliorate the capability to counteract oxidative stress

2019 Experimental Dermatology

47. Patient satisfaction and physician productivity in shared medical appointments for vitiligo. (PubMed)

Patient satisfaction and physician productivity in shared medical appointments for vitiligo. The Shared Medical Appointment (SMA) allows patients with a similar diagnosis to be simultaneously cared for and educated by one provider, which has had success in dermatology and other fields of specialty. The SMA provides a potential solution to improve patient access to dermatologists.The purpose of this study was to implement SMA for vitiligo patients and compare it to traditional appointments (...) with regard to patient satisfaction, time to appointment, number of new patients seen per month, and generated revenue.A vitiligo SMA was implemented and a 12-question survey used to assess satisfaction in both SMA and traditional appointment settings. Satisfaction, revenue, and appointment logistical data for SMA was compared to traditional appointments for new patients.Patients were highly satisfied with both SMA and traditional appointments (p>0.05). Time to appointment was faster for SMA

2019 Journal of American Academy of Dermatology

48. Can we consider silymarin as a treatment option for vitiligo? A double-blind controlled randomized clinical trial of phototherapy plus oral Silybum marianum product versus phototherapy alone. (PubMed)

Can we consider silymarin as a treatment option for vitiligo? A double-blind controlled randomized clinical trial of phototherapy plus oral Silybum marianum product versus phototherapy alone. Vitiligo is a chronic skin disorder caused by destruction of the skin melanocytes, which presents as a depigmented area in the skin. This study examined the effect of Phototherapy plus oral Silybummarianum on the treatment of skin lesions of Vitiligo.In this randomized controlled clinical trial, 34 (...) patients with vitiligo who were referred to Dermatology Clinic of Shahid Faghihi Hospital, Shiraz, Iran, were randomly divided into two groups. The first group was treated with phototherapy plus Narrowband UVB plus oral silymarin and the other group was treated with phototherapy with placebo. The patients in both groups were evaluated with vitiligo area severity index (VASI) at the beginning and end of the study. SPSS software version 23 was used for statistical analyses.The mean of the VASI score

2019 Journal of Dermatological Treatment

49. Childhood Vitiligo. (PubMed)

Childhood Vitiligo. Vitiligo is a common acquired depigmenting skin disease characterized by a progressive loss of functional melanocytes. It may appear from the first years of life to late adulthood. Childhood vitiligo (CV), defined as vitiligo that begins before the age of 12 years, is common and may differ from post-CV in terms of epidemiology, clinical presentation, comorbidities, and treatment options. Taking into consideration the potential significant psychosocial impact of the disease (...) on both children and their parents, all available therapeutic options must be offered to patients who desire treatment. According to the most recent guidelines, topical corticosteroids, topical calcineurin inhibitors, and narrowband ultraviolet B phototherapy are the most commonly used treatment modalities for vitiligo in children. This review presents recent data regarding the whole spectrum of CV. Differences between CV and post-CV are also discussed.

2019 American journal of clinical dermatology

50. Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo. (PubMed)

Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo. Vitiligo is a cutaneous depigmentation disorder caused by the destruction of epidermal melanocytes. The generation and the skin infiltration of autoreactive CD8+ cytotoxic T cells triggered by oxidative stress play a critical role in vitiligo. High-mobility group protein B1 (HMGB1) is a classic damage-associated molecular pattern (DAMP) molecule with strong (...) proinflammatory effects in inflammatory reactions. A previous study had reported an enhanced expression of HMGB1 in vitiligo lesion, but the role of HMGB1 in cutaneous inflammation of vitiligo was still unknown. In the present study, we initially found that HMGB1 was released from the nucleus of melanocytes in vitiligo perilesional skin. Furthermore, cultured normal human melanocytes (NHMs) could release HMGB1 under the treatment with hydrogen peroxide. Moreover, HMGB1 facilitated the secretion of CXCL16

2019 Journal of Investigative Dermatology

51. Helen Tuckwood: Living with vitiligo

Helen Tuckwood: Living with vitiligo Helen Tuckwood: Living with vitiligo - The BMJ ---> I first noticed two patches of white skin about 10 years ago, when I was 47 years old. The patches were on the inside top of my thighs, symmetrical to each other. I had just returned from a holiday abroad and the white patches stood out. At first they didn’t really bother me because the patches were hidden, but after a time, when they started to spread, I decided to investigate the cause. I read about (...) the possible causes on the internet and concluded that it might be vitiligo. I later visited my doctor who confirmed that this diagnosis was correct. My doctor explained that there wasn’t really any treatment that could halt the progress of this condition. Light treatment was an option, but it would mean visits to the hospital two or three times a week for phototherapy. I can’t remember what other treatments were offered, but I remember thinking that there was no guarantee they would halt the vitiligo

2017 The BMJ Blog

52. Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo. (PubMed)

Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo. Glycyrrhizin has been used clinically for several years due to its beneficial effect on immunoglobulin E (IgE)-induced allergic diseases, alopecia areata and psoriasis. In this study, glycyrrhizin, ultraviolet B light (UVB) or a combination of both were used to treat active-stage generalized vitiligo. One hundred and forty-four patients between the ages of 3 and 48 years were divided (...) into three groups: group A received oral compound glycyrrhizin (OCG); group B received UVB applications twice weekly, and group C received OCG+UVB. Follow-ups were performed at 2, 4, and 6 months after the treatment was initiated. The Vitiligo Area Scoring Index (VASI) and the Vitiligo Disease Activity (VIDA) instrument were used to assess the affected body surface, at each follow-up. Results showed that 77.1, 75.0 and 87.5% in groups A, B and C, respectively, presented repigmentation of lesions

Full Text available with Trip Pro

2016 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

53. Liver X Receptor-α polymorphisms (rs11039155 and rs2279238) are associated with susceptibility to vitiligo (PubMed)

Liver X Receptor-α polymorphisms (rs11039155 and rs2279238) are associated with susceptibility to vitiligo Vitiligo is a complex genetic skin depigmentation disorder caused by the destruction of melanocyte from the lesional site. Liver X Receptor-α (LXR-α) expression is upregulated in the melanocytes from perilesional skin as compared to the normal skin of vitiligo patient suggesting its involvement in vitiligo pathogenesis. Polymorphisms in LXR-α have been associated with several diseases (...) including cardiovascular disease, polycystic ovary syndrome, cancer, inflammatory bowel disease and diabetes. In this study, for the first time, we have investigated the association of LXR-α gene polymorphisms and risk of vitiligo. Sixty six vitiligo patients and 75 matched healthy control subjects who did not have any history of vitiligo or any other autoimmune disorder were recruited. The DNA isolated from patients and healthy controls was genotyped by polymerase chain reaction-restriction fragment

Full Text available with Trip Pro

2016 Meta gene

54. The effect of topical piperine combined with narrowband UVB on vitiligo treatment: A clinical trial study. (PubMed)

The effect of topical piperine combined with narrowband UVB on vitiligo treatment: A clinical trial study. Vitiligo is the most common acquired hypopigmentary disease in the community. Piperine as an herbal extract derived from black pepper has strong impact on the melanocyte proliferation and adverse side effects less than synthetic drugs such as corticosteroids. For the first time, this study was aimed to evaluate the effect of topical piperine combined with narrowband ultraviolet B (NB-UVB (...) ) on vitiligo treatment. In this double-blind clinical trial, 63 patients with facial vitiligo were randomly divided into 2 groups: treated with piperine (case) and placebo (control). Also, both groups received NB-UVB phototherapy every other day for 3 months. In the case group, 10 patients have burning sensation on their skin areas (p value = .002). Also, redness of the treated areas was observed in 6 patients (p value = .028). Both side effects were temporary. Regarding repigmentation at time intervals

2018 Phytotherapy research : PTR

55. Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: A prospective, randomized comparative trial. (PubMed)

Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: A prospective, randomized comparative trial. Multiple treatment options are introduced in treatment of vitiligo but the response is unsatisfactory.In this prospective, randomized, comparative trial, we studied the effect of combined treatment with fractional carbon dioxide (CO2 ) laser, platelet-rich plasma (PRP) injection, and narrowband (...) ultraviolet B (NB-UVB) for stable nonsegmental vitiligo regarding repigmentation grade, patient's satisfaction, and side effects.Eighty adult patients with localized nonsegmental vitiligo were enrolled in this study. The patients were randomly categorized to receive 4 lines of treatment; fractional CO2 laser, PRP, combined fractional CO2 laser and PRP, and combined fractional CO2 laser and NB-UVB. The treatment period was 2 months. Patients were clinically evaluated 3 months after the last treatment

2018 Journal of cosmetic dermatology

56. Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol. (PubMed)

Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol. Vitiligo is a pigmentary disorder of skin affecting at least 1% of the world population of all races in both sexes. Its importance is mainly due to subsequent social and psychological problems rather than clinical complications. Various treatment choices are available for vitiligo; however, laser-based courses have shown to give more acceptable results.The aim of this trial was to evaluate the efficacy (...) of Er:YAG laser as a supplementary medicine to topical 5FU and clobetasol in vitiligo patients.Two comparable vitiligo patches from 38 eligible patients were randomized to receive topical 5FU and clobetasol in control group and additional Er:YAG laser in intervention group. Major outcomes of interest were the size of patch and pigmentation score at randomization and 2 and 4 months after therapy.Final sample included 18 (47%) male patients and age of 35.66±8.04. The performance Er:YAG group was superior

2018 Journal of cosmetic dermatology

57. Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial. (PubMed)

Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial. Rhododendrol (RD), 4-(4-hydroxyphenyl)-2-butanol, inhibits melanin synthesis and has been used for skin-whitening cosmetic products. RD has been very effective in lightening skin pigmentation, but some persons have developed so-called RD vitiligo, in which vitiligo starts on the face, neck and hands where topical RD has been applied and even extended over skin areas where RD has not been (...) applied. RD vitiligo lesions in some patients have lasted for years and have been resistant to conventional vitiligo treatments. We examined the effects of cholecalciferol on RD vitiligo in a blinded randomized clinical trial. Forty-eight female RD vitiligo patients were recruited for the trial and were randomized into two groups: the vitamin D (VD)-intervention group that received daily 5000 IU cholecalciferol for 5 months and the control group. Three blinded investigators scored vitiligo improvement

2018 The Journal of dermatology

58. Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. (PubMed)

Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. 29617528 2018 06 13 2168-6084 154 6 2018 Jun 01 JAMA dermatology JAMA Dermatol Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. 725-726 10.1001/jamadermatol.2017.6401 Nguyen Sophie S Department of Dermatology, Université Côte d'Azur, Centre Hospitalier Universitaire Nice, Nice, France. Chuah Sai Yee SY National

2018 JAMA dermatology

59. Preliminary study on the treatment of vitiligo with carbon dioxide fractional laser together with tacrolimus. (PubMed)

Preliminary study on the treatment of vitiligo with carbon dioxide fractional laser together with tacrolimus. Tacrolimus is a conventional medication for the treatment of vitiligo, but the effect of a single medication is limited.This paper aims at observing the effects, adverse responses, and repigmentation results of the joint treatment of vitiligo by Carbon dioxide (CO2 ) fractional laser together with tacrolimus.Forty-five patients with vitiligo were randomly divided into two groups (...) assessments. When the treatment time was increased, the efficacy was also improved, and the repigmentation in the T group occured in three ways: perifollicular repigmentation, marginal repigmentation and diffuse repigmentation. There were three cases of isomorphic responses (2 cases in the rapid progression stage, one case in the progression stage), and 1 case formed scarring on the neck in the T group.The treatment of vitiligo by CO2 fractional laser together with tacrolimus is significantly effective

2018 Lasers in surgery and medicine

60. Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. (PubMed)

Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. 28300320 2018 08 20 2018 08 20 1365-2230 42 3 2017 Apr Clinical and experimental dermatology Clin. Exp. Dermatol. Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. 363-366 10.1111/ced.13056 BinSheikhan S S Department of Dermatology, Zayed Military Hospital, Abu Dhabi, United Arab Emirates (...) . Al Abadie M M http://orcid.org/0000-0002-0727-4632 Department of Dermatology, Royal Wolverhampton NHS Trust, Wolverhampton, and Medical School, Birmingham, West Midlands, UK. eng Journal Article Randomized Controlled Trial England Clin Exp Dermatol 7606847 0307-6938 IM Adolescent Adult Aged Combined Modality Therapy Female Humans Lasers, Excimer therapeutic use Low-Level Light Therapy adverse effects instrumentation Male Middle Aged Needles Vitiligo radiotherapy surgery Young Adult 2016 04 06

2018 Clinical and experimental dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>